Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Marie Jeanneteau"'
Using visual feedback to tune the second vocal tract resonance for singing in the high soprano range
Publikováno v:
Logopedics, phoniatrics, vocology. 47(1)
Over a range roughly C5–C6, sopranos usually tune their first vocal tract resonance (R1) to the fundamental frequency (fo) of the note sung: R1:fo tuning. Those who sing well above C6 usually adjust their second vocal tract resonance (R2) and use R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bfc678b39fad72344a58f0485ae3756
https://pubmed.ncbi.nlm.nih.gov/33121295
https://pubmed.ncbi.nlm.nih.gov/33121295
Autor:
Kelly Airiau, Matías García, Francis Belloc, Marie Jeanneteau, François Moreau-Gaudry, Mahon Fx, Estelle Guérin, Eric Lippert
Publikováno v:
Leukemia. 23:679-685
Imatinib is an effective first-line therapy for chronic myelogenous leukemia (CML) that acts by targeting the tyrosine kinase activity of BCR-ABL. To overcome resistance, second-generation inhibitors of BCR-ABL have been developed. Among these, nilot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecfcecef7942add7c75bf04e73f9d295
https://doi.org/10.1038/leu.2008.364
https://doi.org/10.1038/leu.2008.364
Autor:
Valérie Prouzet-Mauléon, Francis Belloc, Arnaud Pigneux, Kaoutar Allou, Pierre Dubus, Francois-Xavier Mahon, Benoit Rousseau, Manon Giraudon, Marie Jeanneteau, Kelly Airiau
Publikováno v:
Oncotarget
// Kelly Airiau 1, 2 , Valerie Prouzet-Mauleon 1 , Benoit Rousseau 3 , Arnaud Pigneux 1, 2 , Marie Jeanneteau 2 , Manon Giraudon 2 , Kaoutar Allou 1, 2 , Pierre Dubus 4 , Francis Belloc 1, 2, * , Francois-Xavier Mahon 1, 2, * 1 Laboratoire d’Hemato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd8e3c12f9896e109401744038067c86
https://pubmed.ncbi.nlm.nih.gov/26625317
https://pubmed.ncbi.nlm.nih.gov/26625317
Autor:
Marie Jeanneteau, Marina Josselin, Francois-Xavier Mahon, Kelly Airiau, Beatrice Turcq, Francis Belloc
Publikováno v:
Experimental Hematology
Experimental Hematology, Elsevier, 2012, 40 (5), pp.367-378.e2. ⟨10.1016/j.exphem.2012.01.004⟩
Experimental Hematology, Elsevier, 2012, 40 (5), pp.367-378.e2. ⟨10.1016/j.exphem.2012.01.004⟩
International audience; Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now used for the treatment of CML. These TKI induce apoptos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90bbb7b900126134133f5e26e8dbf58
https://pubmed.ncbi.nlm.nih.gov/22240609
https://pubmed.ncbi.nlm.nih.gov/22240609
Autor:
Francois-Xavier Mahon, Marie Jeanneteau, Josy Reiffers, Francis Lacombe, Maialene Uhalde, Arnaud Pigneux, Francis Belloc, Noel Milpied
Publikováno v:
Experimental hematology. 36(12)
Triptolide has shown antitumor activity in a broad range of solid tumors and on leukemic cells in vitro.The THP1 cell line and primary acute myeloid leukemia (AML) cells were cultured with triptolide alone or in association with AraC or idarubicin in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b81fcba85a511fd8fa7aed3f1750d28
https://pubmed.ncbi.nlm.nih.gov/18922616
https://pubmed.ncbi.nlm.nih.gov/18922616
Autor:
Marie Jeanneteau, Maïalen Uhalde, Francois-Xavier Mahon, Francis Belloc, Laurie Cazalis, François Moreau-Gaudry, Francis Lacombe, Vincent Praloran
Publikováno v:
Cancer biologytherapy. 6(6)
It is an important challenge to better understand the mechanisms of tyrosine kinase inhibitors-induced apoptosis in CML cells. Thus, we have investigated how this apoptosis can be modulated by extracellular factors. Apoptosis induced by imatinib and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a306f5463873fd8e3f042092c3c87bbd
https://pubmed.ncbi.nlm.nih.gov/17538248
https://pubmed.ncbi.nlm.nih.gov/17538248
Publikováno v:
Cell Death & Disease
Nilotinib is a second-generation tyrosine kinase inhibitor, designed to specifically inhibit break-point cluster region (BCR)-Abelson (ABL) and developed to treat chronic myeloid leukemia (CML) in patients showing a resistance to imatinib. We previou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e027ac537799f5200048400e30ad778
http://europepmc.org/articles/PMC3824646
http://europepmc.org/articles/PMC3824646
Publikováno v:
Blood. 114:3246-3246
Abstract 3246 Poster Board III-183 Introduction BCR-ABL confers to several cell lines an apoptosis-resistant phenotype that is critically dependent on its kinase activity. It has been shown that BCR-ABL can block the mitochondrial step of apoptosis a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92650a8cbf22b54b99fe5e835b7a214d
https://doi.org/10.1182/blood.v114.22.3246.3246
https://doi.org/10.1182/blood.v114.22.3246.3246
Autor:
François Moreau-Gaudry, Estelle Guérin, Francis Belloc, Eric Lippert, Francois-Xavier Mahon, Kelly Airiau, Melissa Garcia, Marie Jeanneteau, Vanessa Augis
Publikováno v:
Blood. 112:4218-4218
Imatinib is an effective first line therapy for early chronic phase chronic myelogenous leukaemia (CML) that acts by targeting the tyrosine kinase activity of BCR-ABL. However, mutations occurred that procure imatinib resistance and, to overcome this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caa3af5a3b4a251c4811b0af76960b2c
https://doi.org/10.1182/blood.v112.11.4218.4218
https://doi.org/10.1182/blood.v112.11.4218.4218